Sign in
ATHA Stock Price, Chart, Stats & News
Athira Pharma, Inc.
Save
26.62M
Market cap
–
Current P/E
–
Forward P/E
ATHA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -125.61% |
ROE | -107.06% |
D/E | 0.03x |
Interest coverage ratio | – |
ATHA valuation
P/E | – |
P/S | – |
P/B | 0.99x |
P/CF | -0.51x |
P/FCF | -0.51x |
P/OCF | -0.51x |
PEG | -0.02x |
EV multiple | -1.24x |
About
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue